Literature DB >> 31548219

Acute Megakaryocytic Leukemia.

Maureen McNulty1, John D Crispino1.   

Abstract

Acute megakaryoblastic leukemia (AMKL) is a rare malignancy affecting megakaryocytes, platelet-producing cells that reside in the bone marrow. Children with Down syndrome (DS) are particularly prone to developing the disease and have a different age of onset, distinct genetic mutations, and better prognosis as compared with individuals without DS who develop the disease. Here, we discuss the contributions of chromosome 21 genes and other genetic mutations to AMKL, the clinical features of the disease, and the differing features of DS- and non-DS-AMKL. Further studies elucidating the role of chromosome 21 genes in this disease may aid our understanding of how they function in other types of leukemia, in which they are frequently mutated or differentially expressed. Although researchers have made many insights into understanding AMKL, much more remains to be learned about its underlying molecular mechanisms.
Copyright © 2020 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31548219      PMCID: PMC6996441          DOI: 10.1101/cshperspect.a034884

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Med        ISSN: 2157-1422            Impact factor:   6.915


  112 in total

Review 1.  Transient myeloproliferative disorder, a disorder with too few data and many unanswered questions: does it contain an important piece of the puzzle to understanding hematopoiesis and acute myelogenous leukemia?

Authors:  Alan S Gamis; Joanne M Hilden
Journal:  J Pediatr Hematol Oncol       Date:  2002-01       Impact factor: 1.289

2.  The landscape of somatic mutations in Down syndrome-related myeloid disorders.

Authors:  Kenichi Yoshida; Tsutomu Toki; Yusuke Okuno; Rika Kanezaki; Yuichi Shiraishi; Aiko Sato-Otsubo; Masashi Sanada; Myoung-ja Park; Kiminori Terui; Hiromichi Suzuki; Ayana Kon; Yasunobu Nagata; Yusuke Sato; RuNan Wang; Norio Shiba; Kenichi Chiba; Hiroko Tanaka; Asahito Hama; Hideki Muramatsu; Daisuke Hasegawa; Kazuhiro Nakamura; Hirokazu Kanegane; Keiko Tsukamoto; Souichi Adachi; Kiyoshi Kawakami; Koji Kato; Ryosei Nishimura; Shai Izraeli; Yasuhide Hayashi; Satoru Miyano; Seiji Kojima; Etsuro Ito; Seishi Ogawa
Journal:  Nat Genet       Date:  2013-09-22       Impact factor: 38.330

Review 3.  Pattern of malignant disorders in individuals with Down's syndrome.

Authors:  H Hasle
Journal:  Lancet Oncol       Date:  2001-07       Impact factor: 41.316

4.  miR-125b-2 is a potential oncomiR on human chromosome 21 in megakaryoblastic leukemia.

Authors:  Jan-Henning Klusmann; Zhe Li; Katarina Böhmer; Aliaksandra Maroz; Mia Lee Koch; Stephan Emmrich; Frank J Godinho; Stuart H Orkin; Dirk Reinhardt
Journal:  Genes Dev       Date:  2010-03-01       Impact factor: 11.361

5.  Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.

Authors:  Liat Rainis; Dan Bercovich; Sabine Strehl; Andrea Teigler-Schlegel; Batia Stark; Jan Trka; Ninette Amariglio; Andrea Biondi; Inna Muler; Gideon Rechavi; Helena Kempski; Oskar A Haas; Shai Izraeli
Journal:  Blood       Date:  2003-03-20       Impact factor: 22.113

6.  Role for MKL1 in megakaryocytic maturation.

Authors:  Ee-Chun Cheng; Qing Luo; Emanuela M Bruscia; Matthew J Renda; James A Troy; Stephanie A Massaro; David Tuck; Vincent Schulz; Shrikant M Mane; Nancy Berliner; Yi Sun; Stephan W Morris; Caihong Qiu; Diane S Krause
Journal:  Blood       Date:  2009-01-09       Impact factor: 22.113

7.  Exome sequencing identifies putative drivers of progression of transient myeloproliferative disorder to AMKL in infants with Down syndrome.

Authors:  Sergey I Nikolaev; Federico Santoni; Anne Vannier; Emilie Falconnet; Emanuela Giarin; Giuseppe Basso; Alexander Hoischen; Joris A Veltman; Jurgen Groet; Dean Nizetic; Stylianos E Antonarakis
Journal:  Blood       Date:  2013-06-03       Impact factor: 22.113

8.  Highly penetrant myeloproliferative disease in the Ts65Dn mouse model of Down syndrome.

Authors:  Gina Kirsammer; Sarah Jilani; Hui Liu; Elizabeth Davis; Sandeep Gurbuxani; Michelle M Le Beau; John D Crispino
Journal:  Blood       Date:  2007-09-27       Impact factor: 22.113

Review 9.  Transcription factors in late megakaryopoiesis and related platelet disorders.

Authors:  M R Tijssen; C Ghevaert
Journal:  J Thromb Haemost       Date:  2013-04       Impact factor: 5.824

10.  Characterization of novel genomic alterations and therapeutic approaches using acute megakaryoblastic leukemia xenograft models.

Authors:  Clarisse Thiollier; Cécile K Lopez; Bastien Gerby; Cathy Ignacimouttou; Sandrine Poglio; Yannis Duffourd; Justine Guégan; Paola Rivera-Munoz; Olivier Bluteau; Vinciane Mabialah; M'boyba Diop; Qiang Wen; Arnaud Petit; Anne-Laure Bauchet; Dirk Reinhardt; Beat Bornhauser; Daniel Gautheret; Yann Lecluse; Judith Landman-Parker; Isabelle Radford; William Vainchenker; Nicole Dastugue; Stéphane de Botton; Philippe Dessen; Jean-Pierre Bourquin; John D Crispino; Paola Ballerini; Olivier A Bernard; Françoise Pflumio; Thomas Mercher
Journal:  J Exp Med       Date:  2012-10-08       Impact factor: 14.307

View more
  3 in total

Review 1.  Clinical and biological aspects of myeloid leukemia in Down syndrome.

Authors:  Austin C Boucher; Kenneth J Caldwell; John D Crispino; Jamie E Flerlage
Journal:  Leukemia       Date:  2021-09-13       Impact factor: 12.883

2.  Stepwise GATA1 and SMC3 mutations alter megakaryocyte differentiation in a Down syndrome leukemia model.

Authors:  Brahim Arkoun; Elie Robert; Fabien Boudia; Stefania Mazzi; Virginie Dufour; Aurélie Siret; Yasmine Mammasse; Zakia Aid; Matthieu Vieira; Imanci Aygun; Marine Aglave; Marie Cambot; Rachel Petermann; Sylvie Souquere; Philippe Rameau; Cyril Catelain; Romain Diot; Gérard Tachdjian; Olivier Hermine; Nathalie Droin; Najet Debili; Isabelle Plo; Sébastien Malinge; Eric Soler; Hana Raslova; Thomas Mercher; William Vainchenker
Journal:  J Clin Invest       Date:  2022-07-15       Impact factor: 19.456

3.  Dissecting stepwise mutational impairment of megakaryopoiesis in a model of Down syndrome-associated leukemia.

Authors:  Edward J Evans; James DeGregori
Journal:  J Clin Invest       Date:  2022-07-15       Impact factor: 19.456

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.